Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.48 |
| ▸ | CFTR | P13569 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | BRS3 | P32247 | 11/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19616741 | 0.86 | C5AR1 (0.47) | C5AR1CFTRBRS3 | |
| SCHEMBL25196759 | 0.86 | KDM4E (0.58) | C5AR1KDM4EALDH1A1HPGDHIF1A | |
| SCHEMBL22440265 | 0.84 | C5AR1 (0.46) | C5AR1CFTRKDM4EALDH1A1HPGD | |
| SCHEMBL19947816 | 0.83 | C5AR1 (0.44) | C5AR1CFTRKDM4EALDH1A1HPGD | |
| SCHEMBL1831098 | 0.83 | BRS3 (0.57) | C5AR1KDM4EALDH1A1HPGDHIF1A | |
| SCHEMBL19948738 | 0.83 | C5AR1 (0.45) | C5AR1CFTRKDM4EALDH1A1HPGD | |
| SCHEMBL19948214 | 0.83 | C5AR1 (0.45) | C5AR1CFTRKDM4EALDH1A1HPGD | |
| SCHEMBL25324710 | 0.83 | C5AR1 (0.44) | C5AR1CFTRKDM4EALDH1A1HPGD | |
| SCHEMBL22440319 | 0.81 | C5AR1 (0.46) | C5AR1CFTRKDM4EALDH1A1BRS3 | |
| SCHEMBL23075017 | 0.81 | TLR9 (0.44) | C5AR1BRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111989321-A | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2020-11-24 | — | — | CN | disclosed |
| US-10647715-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190270743-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647715-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | C5AR1 4146/4885CFTR 95/4885KDM4E 3689/4885 |
| US-20190270743-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | C5AR1 4146/4885CFTR 95/4885KDM4E 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.